Alan Baptist, MD
Allergy & Immunology · Ann Arbor, MINPI 1043257751
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,113 of the $167,930 with a category attached, or 78.1%. 21 manufacturers reported payments, led by GSK at 37.1% of the total. Among allergy & immunology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $770.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$62K
- CSL Behring$27K
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- AstraZeneca$14K
- Biocryst Pharmaceuticals, Inc.$11K
- Teva Pharmaceuticals USA, Inc.$10K
- plus $22K from 15 others
Across 639 payments — averaging $3583.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Takeda Pharmaceuticals U.S.A., Inc.$502K
- Biocryst Pharmaceuticals, Inc.$119K
- Regeneron$111K
- Incyte Corporation$92K
- Shire North American Group Inc$91K
- plus $209K from 8 others
What the payments were for
- Consulting fees$131,11378%
- Speaking & faculty fees$19,65012%
- Travel & lodging$8,9555%
- Food & beverage$8,2135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $62,262 |
| CSL Behring | 29 | $27,305 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $21,784 |
| AstraZeneca | 33 | $14,082 |
| Biocryst Pharmaceuticals, Inc. | 24 | $11,271 |
| Teva Pharmaceuticals USA, Inc. | 19 | $9,506 |
| Sanofi US Services Inc. | 4 | $4,538 |
| Regeneron | 4 | $4,344 |
| Biocryst US Sales Co., LLC | 6 | $3,135 |
| Novartis | 6 | $2,588 |
| Regeneron Healthcare Solutions, Inc. | 6 | $2,461 |
| Alk-abello, Inc | 6 | $1,773 |
| Cycle Pharmaceuticals Inc | 1 | $1,034 |
| Genentech USA, Inc. | 1 | $880 |
| Sanofi | 6 | $484 |
| Genentech, Inc. | 3 | $165 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Optinose US, Inc. | 1 | $90 |
| Blueprint Medicines Corporation | 1 | $46 |
| Amgen | 2 | $46 |
| Pharming Healthcare, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$27,300
- TAKHZYRO$16,643
- AIRSUPRA$10,779
- Orladeyo$10,475
- Andembry$8,094
- Hizentra$7,131
- DUPIXENT$6,909
- Haegarda$5,969
- EOHILIA$4,290
- AYVAKIT$2,355
- NUCALA$1,414
- AirDuo Digihaler$1,131
- Nityr$1,034
- ProAir Digihaler$1,006
- ArmonAir Digihaler$1,006
- XOLAIR$996
- FASENRA$258
- Albuterol Sulfate$122
- LIBERVANT$119
- CINQAIR$102
How this compares
$167,930 in reported general payments places this provider in the 90th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 19 | $73,349 |
| Dupixent PenDupilumab | 17 | $63,905 |
| TezspireTezepelumab-Ekko | 11 | $48,341 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,696 |
| DuleraMometasone/Formoterol | 13 | $4,354 |
| Azelastine Hcl | 16 | $264 |
| Montelukast Sodium | 14 | $207 |
| Fluticasone Propionate | 13 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $165 | $73,34919 claims |
| AstraZenecaTezspire | $14,082 | $48,34111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Ann Arbor
- James BakerAnn Arbor$17K
- Malika GuptaAnn Arbor$5K
- Ian SlackAnn Arbor$2K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Mohsen NasirSaginaw$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.